2023-503624-83-00CompletedPhase 1/2
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
Source: EU CTIS (euclinicaltrials.eu) · Last updated 19 Mar 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 90 (actual)
- First submitted
- 28 Jun 2024
- Start date
- 16 Aug 2021
- Lead sponsor
- Incyte Corp.
- Diseases
- Myeloproliferative neoplasms
- EU CT number
- 2023-503624-83-00
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 90
- 8 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (8)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier Universitaire D'Angers | Angers | France | Completed |
| Institut Paoli-Calmettes | Marseille | France | Completed |
| Hopital Saint Louis | Paris | France | Completed |
| Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII | Bergamo | Italy | Completed |
| Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico | Bologna | Italy | Completed |
| Careggi University Hospital | Florence | Italy | Completed |
| Azienda Ospedaliero-Universitaria San Luigi Gonzaga | Orbassano | Italy | Completed |
| Hospital Santa Maria Della Misericordia | Perugia | Italy | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.